Gastrointestinal Cancer Science Highlights
This session highlights five of the most clinically relevant abstracts within the Gastrointestinal track of the 2022 ASTRO Annual Meeting Scientific Program. These noteworthy scientific abstracts share important findings and feature cutting edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended.
Highlighted Abstracts include –
- NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
- Long Term Result of a Multi-institutional Phase II Study of Hypofractionated Proton Beam Irradiation of Unresectable Primary Liver Tumors
- Patient-reported Outcomes (PROs) in NRG Oncology RTOG 1010: Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2 Overexpressing (HER2+) Esophageal Adenocarcinoma (EAC)
- Multi-Institutional Comparison of Ablative Radiation Therapy in 5 vs. 15-25 Fractions for Locally Advanced Pancreatic Cancer
- Non-operative Management is Feasible and Safe in Patients with Rectal Cancer who Achieve Clinical Complete Response to Short-course Radiation Therapy and Consolidation Chemotherapy
This activity is available from August 29, 2023, through 11:59 p.m. Eastern time on December 31, 2023.
This activity was originally recorded at ASTRO’s 2022 Annual Meeting.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists.
Upon completion of this activity, participants:
- Have had the opportunity to increase knowledge of clinical trials of outcomes when using hypofractionated radiation therapy for extremity soft tissue sarcoma
- Gain knowledge of the use and technique of radiation therapy for skin cancers
- When appropriate, implement the advances in radiation oncology that help improve patient outcomes and quality of life.
Discussant: Sunil Krishnan, MD, Institute of Molecular Medicine, UTHealth, Houston
- Research funding from NIH and DOD
- Taylor and Francis book royalties
- Patents related to nanoparticles, minibeams, fullerenes that are unrelated to the presentation
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the free member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until December 31, 2023, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.